Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850349 | 0.86 | KCNH2 (0.50) | MEN1KMT2AKCNH2MAPTALDH1A1 | |
| SCHEMBL22659816 | 0.83 | MAPT (0.46) | MEN1KMT2ATSHRKCNH2MAPT | |
| SCHEMBL17088578 | 0.83 | KCNH2 (0.48) | MEN1KMT2ATSHRKCNH2MAPT | |
| SCHEMBL29403310 | 0.83 | MAPT (0.59) | MEN1KMT2AKCNH2MAPTALDH1A1 | |
| SCHEMBL11350806 | 0.83 | MAPT (0.59) | MEN1KMT2AKCNH2MAPTALDH1A1 | |
| SCHEMBL21783120 | 0.79 | CYP1A2 (0.46) | MEN1KMT2ATSHRKCNH2MAPT | |
| SCHEMBL22659365 | 0.79 | CYP1A2 (0.48) | MEN1KMT2ATSHRMAPTALDH1A1 | |
| SCHEMBL741169 | 0.78 | KMT2A (0.54) | MEN1KMT2ATSHRKCNH2MAPT | |
| SCHEMBL9720686 | 0.77 | MEN1 (0.65) | MEN1KMT2ATSHRMAPTALDH1A1 | |
| SCHEMBL31693367 | 0.77 | MEN1 (0.65) | MEN1KMT2ATSHRMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448265-B1 | CORTICOTROPIN RELEASING FACTOR(CRF); ANTIDEPRESSANT; (5-AMINO-1-(2,6-DICHLORO-4-TRIFLUOROMETHYLPHENYL)-3-METHYLSULFANYL-1H -PYRAZOL-4-YL)-(2,5-DIMETHYLPHENYL)METHANONE FOR EXAMPLE | PFIZER, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441018-B2 | TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES. | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHAN (US) | 2002-04-25 | — | — | US | disclosed |
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHEN (US) | 2002-02-07 | — | — | US | disclosed |
| US-6103900-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST WHICH TREAT STRESS-INDUCED DISEASES | PFIZER INC (US) | 2000-08-15 | — | — | US | disclosed |
| US-6005109-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY; EFFECTIVE IN THE TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES | PFLIZER INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0674624-B1 | PYRAZOLES HAVING CRF ANTAGONIST ACTIVITY | PFIZER (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5712303-A | ANTIDEPRESSANTS | PFIZER INC. (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0674624-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| CN-1092768-A | Pyrazoles and pyrazolopyrimidine | PFIZER (US) | 1994-09-28 | — | — | CN | disclosed |
| WO-1994013643-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | CRH, CRHR1, CRHR2 | MEN1 2637/4885KMT2A 4103/4885TSHR 232/4885 |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | CRH, CRHR1, CRHR2 | MEN1 2637/4885KMT2A 4103/4885TSHR 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.